REDWOOD CITY, Calif., May 21, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. has been named a TiE50 Winner. The TiE50 award was presented in Santa Clara, CA at TiEcon 2012, an annual convention hosted by The Indus Entrepreneurs (TiE), an organization dedicated to fostering entrepreneurs. The TiE50 awards program recognizes the top technology startups from the following segments: internet, energy, wireless/mobile, software and life sciences. Pearl’s award was made in the life sciences category and was based on an expert panel’s assessment of Pearl’s intellectual property, business model and management team.
Chuck Bramlage, Pearl’s chief executive officer commented on the award, “The TiE organization awards start-ups that put a premium on entrepreneurial spirit, technological excellence and business progression. At Pearl, we share the importance TiE places on these values. Since our first funding in 2007, we have built an experienced team of professionals in clinical, regulatory, product development, quality, business and finance; raised over $100 million in venture capital; and discovered solutions to unaddressed drug development and drug delivery challenges. These elements have allowed us to progress a family of bronchodilator products for COPD patients while conforming to the strictest product development standards and maintaining a capital efficient business plan. We believe that these foundations will serve us well as we prepare to enter late stage clinical development, and will provide a return on the capital invested in the company thus far.”
About TiE
TiE is a global network dedicated to fostering entrepreneurs across its international network. Sponsored by top venture capital firms and Fortune 500 corporations, TiE’s network has grown across 56 chapters in 13 countries comprising of 1,800 experienced entrepreneurs and business executives as charter members, 12,000 aspiring entrepreneurs and professionals as members.
TiEcon 2012 took place at Santa Clara Convention Center, May 18-19. The event featured star keynotes, 20 hot topic panel sessions with the industry leaders in entrepreneurship, social, mobile, cloud, energy and life sciences, over 150 innovative company exhibits, and networking with VCs, executives, founders and technology professionals. For more information, please visit www.tiecon.org.
About Pearl Therapeutics
Pearl Therapeutics is a privately held company developing combination therapies for the treatment of highly prevalent respiratory diseases, including chronic obstructive pulmonary disease and asthma. Pearl is rapidly advancing a pipeline of products including PT003, an inhaled, fixed-dose combination bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl’s proprietary porous particle cosuspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.
SOURCE Pearl Therapeutics Inc.
